Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Target Raised at The Goldman Sachs Group

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target boosted by investment analysts at The Goldman Sachs Group from $654.00 to $725.00 in a report issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the pharmaceutical company’s stock. The Goldman Sachs Group‘s price objective would suggest a potential upside of 35.70% from the company’s previous close.

VRTX has been the subject of a number of other research reports. Sanford C. Bernstein upgraded Vertex Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, July 29th. Jefferies Financial Group increased their target price on Vertex Pharmaceuticals from $633.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, September 23rd. Weiss Ratings raised Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, October 16th. Morgan Stanley began coverage on Vertex Pharmaceuticals in a research note on Tuesday, September 1st. They issued an “overweight” rating and a $665.00 price target for the company. Finally, Barclays upped their price objective on Vertex Pharmaceuticals from $615.00 to $617.00 and gave the company an “overweight” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $595.74.

Vertex Pharmaceuticals Stock Down 3.4%

Shares of NASDAQ VRTX traded down $18.88 during mid-day trading on Tuesday, reaching $534.27. 1,204,990 shares of the company were exchanged, compared to its average volume of 1,388,479. The stock has a market capitalization of $135.60 billion, a P/E ratio of 31.06, a P/E/G ratio of 2.54 and a beta of 0.28. The company’s 50-day simple moving average is $523.32 and its 200-day simple moving average is $479.96. Vertex Pharmaceuticals has a twelve month low of $403.16 and a twelve month high of $568.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The company had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The firm’s quarterly revenue was up 11.8% on a year-over-year basis. During the same quarter last year, the company posted $4.80 EPS. As a group, equities research analysts expect that Vertex Pharmaceuticals will post 16.74 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Community Financial Services Group LLC bought a new position in Vertex Pharmaceuticals during the 2nd quarter worth $26,000. Meeder Asset Management Inc. bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $26,000. MADDEN SECURITIES Corp bought a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at $26,000. Elevation Wealth Partners LLC lifted its position in shares of Vertex Pharmaceuticals by 103.7% during the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 28 shares during the period. Finally, Pingora Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth $32,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue increased 11.8% year over year to $3.44 billion, exceeding the $3.42 billion consensus estimate. Growth was supported by the cystic fibrosis franchise and increasing contributions from newer products, including CASGEVY and JOURNAVX. Vertex Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Several analysts raised their price targets after the earnings release. RBC lifted its target to $600 with an “outperform” rating, Wells Fargo raised its target to $650 with an “overweight” rating, Cantor Fitzgerald increased its target to $619 with an “overweight” rating, and Stifel raised its target to $563 while maintaining a “hold” rating. Wells Fargo analyst update
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $13.2 billion-$13.3 billion and highlighted continued portfolio diversification, pipeline progress, and the completed acquisition of Crinetics Pharmaceuticals. Vertex third-quarter results
• Neutral Sentiment: The company’s outlook is broadly in line with Wall Street’s $13.3 billion revenue estimate, limiting the positive impact of the guidance increase. Investors will focus on whether newer launches can offset the eventual transition within the cystic fibrosis business.
• Negative Sentiment: Third-quarter adjusted earnings of $4.76 per share fell short of consensus estimates ranging from $4.82 to $4.92 and declined from $4.80 a year earlier. Vertex misses third-quarter earnings estimates
• Negative Sentiment: Higher investment in new product launches and the Crinetics transaction kept profit growth from matching revenue growth, creating concern that elevated spending could weigh on near-term margins.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.